Section one: Contracting authority/entity
one.1) Name and addresses
BELFAST HEALTH AND SOCIAL CARE TRUST
LISBURN ROAD
BELFAST
BT97AB
Contact
Norma Moore
norma.moore@belfasttrust.hscni.net
Country
United Kingdom
Region code
UKN06 - Belfast
Internet address(es)
Main address
https://belfasttrust.hscni.net
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
Reference number
DAC10464
two.1.2) Main CPV code
- 33000000 - Medical equipments, pharmaceuticals and personal care products
two.1.3) Type of contract
Supplies
two.1.4) Short description
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £1,000,000
two.2) Description
two.2.3) Place of performance
NUTS codes
- UKN - Northern Ireland
Main site or place of performance
Belfast Health and Social Care Trust
two.2.4) Description of the procurement
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
two.2.5) Award criteria
Price
two.2.11) Information about options
Options: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Negotiated without a prior call for competition
- The works, supplies or services can be provided only by a particular economic operator for the following reason:
- protection of exclusive rights, including intellectual property rights
Explanation:
No other reasonable alternative or substitute exists for this procurement and the absence of competition is not a result of the artificial narrowing of the parameters of the procurement. Lutetium (177Lu) oxodetreotide (Lutathera) is a licensed radiopharmaceutical for the treatment of unresectable or metastatic, progressive, well-differentiated somatostatin receptor positive gastro-entero-pancreatic neuroendocrine (GEP) tumours in adults. The supplier, Advanced Accelerator Applications (AAA), holds the unique patent and licence for this product. This is the only licenced Peptide Receptor Radionuclide Therapy (PRRT) in Europe.
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
Section five. Award of contract/concession
Contract No
DAC10464
Title
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
A contract/lot is awarded: Yes
five.2) Award of contract/concession
five.2.1) Date of conclusion of the contract
9 May 2022
five.2.2) Information about tenders
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor/concessionaire
Advanced Accelerator Applications (UK & Ireland) Ltd
Edison House, 223-231 Old Marylebone Road
London
NW1 1QT
Country
United Kingdom
NUTS code
- UKI - London
Internet address
The contractor/concessionaire is an SME
No
five.2.4) Information on value of contract/lot/concession (excluding VAT)
Initial estimated total value of the contract/lot/concession: £1,000,000
Total value of the contract/lot/concession: £1,000,000
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
Belfast Health and Social Care Trust
Belfast
BT8 8BH
norma.moore@belfasttrust.hscni.net
Country
United Kingdom